Literature DB >> 24922670

Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis.

Hiroki Nishikawa1, Ryuichi Kita2, Toru Kimura2, Yoshiaki Ohara2, Haruhiko Takeda2, Azusa Sakamoto2, Sumio Saito2, Norihiro Nishijima2, Akihiro Nasu2, Hideyuki Komekado2, Yukio Osaki2.   

Abstract

AIM: To compare clinical outcome in patients with Child-Pugh C hepatocellular carcinoma (HCC) treated with non-transplant therapies and those treated with best supportive care. PATIENTS AND METHODS: A total of 182 patients with HCC with Child-Pugh C cirrhosis were analyzed. Patients were classified into two groups: patients treated with non-transplant therapies (n=113, treated group) and untreated patients (n=69, untreated group). Furthermore, for reducing the bias in patient selection, a propensity score matching analysis was performed (55 pairs).
RESULTS: The median survival time in the treated group was significantly longer than that in the untreated group (1.16 years vs. 0.21 years, p<0.001). After propensity score matching, the median survival time in the treated group remained significantly longer than that in the untreated group (0.95 years vs. 0.17 years, p=0.01).
CONCLUSION: In patients with HCC with Child-Pugh C cirrhosis, those treated with non-transplant therapies might have longer survival than untreated patients. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Child-Pugh C; Hepatocellular carcinoma; best supportive care; non-transpalnt therapies; overall survival

Mesh:

Year:  2014        PMID: 24922670

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

Authors: 
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

2.  Management of Hepatocellular Carcinoma in Japan as a World-Leading Model.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-12-13       Impact factor: 11.740

Review 3.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

4.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.